Skip to search formSkip to main contentSkip to account menu

RG7652

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Monoclonal Antibodies

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Combined administration of RG7652, a recombinant human monoclonal antibody against PCSK9, and atorvastatin does not result in reduction of immune function.
RG7652 is a human IgG1 monoclonal antibody designed to inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) binding to… 
2014
2014
Critical role of bioanalytical strategies in investigation of clinical PK observations, a Phase I case study
RG7652 is a human immunoglobulin 1 (IgG1) monoclonal antibody (mAb) targeting proprotein convertase subtilisin/kexin type 9… 
Review
2013
Review
2013
Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study
Purpose: Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates hepatic LDL receptors, playing a key role in cholesterol… 
2013
2013
Abstract 12009: Effect of RG7652, a mAb Against PCSK9, on Apolipoprotein B, Oxidized LDL, Lipoprotein(a) and Lipoprotein-Associated Phospholipase A2 in Healthy Individuals With Elevated LDL-c
Background: RG7652 (MPSK3169A) is a fully human IgG1 monoclonal antibody (mAb) directed against proprotein convertase subtilisin… 
Review
2013
Review
2013
GW24-e2907 Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose…
Objectives Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates hepatic LDL receptors, playing a key role in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)